Oramed Pharmaceuticals (ORMP) Total Current Liabilities (2011 - 2026)

Oramed Pharmaceuticals' Total Current Liabilities history runs 16 years deep, the most recent figure standing at $10.6 million for Q1 2026.

• Quarterly Total Current Liabilities rose 92.33% year-over-year to $10.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $10.6 million (up 92.33% YoY) and the FY2025 annual result came in at $19.1 million, up 235.73% from the prior year.
• Total Current Liabilities was $10.6 million for Q1 2026 at Oramed Pharmaceuticals, down from $19.1 million in the prior quarter.
• Across five years, Total Current Liabilities topped out at $78.2 million in Q3 2023 and bottomed at $1.1 million in Q2 2023.
• A 5-year average of $15.0 million and a median of $6.1 million in 2025 frame the typical range for Total Current Liabilities.
• Annual changes were most pronounced in 2023 — Total Current Liabilities surged 1098.08% — and 2024, when it sank 93.25%.
• Oramed Pharmaceuticals' Total Current Liabilities stood at $5.7 million in 2022, then soared by 826.11% to $53.2 million in 2023, then sank by 89.32% to $5.7 million in 2024, then jumped by 235.73% to $19.1 million in 2025, then tumbled by 44.66% to $10.6 million in 2026.
• Business Quant data shows ORMP's Total Current Liabilities at $10.6 million in Q1 2026, $19.1 million in Q4 2025, and $6.1 million in Q3 2025.